People are using peptides to treat anxiety and low mood. There's no protocol for that.

Anxiety, exhaustion, and low mood are now a top reason people go looking at peptides. Not fat loss, not recovery, not longevity. They feel flat or wired or burned out, the standard route (a GP, a waitlist, an SSRI that takes six weeks) feels slow, and a forum thread promises something faster.

The problem: there is almost no protocol guidance for this use case. In our read of the community, a representative thread asking for the "best peptide for brain fog and mood" drew 28 comments of suggestions with no authoritative answer. That is the pattern across the mental-health entry point: real demand, and a guidance layer that does not exist yet.

Here is what the evidence actually supports, what it does not, and why none of it is a substitute for psychiatric care.

The peptides actually marketed for mood

A handful of compounds get sold specifically for anxiety, focus, and mood. The honest summary is that the evidence is thin and mostly non-Western.

Semax and Selank

These are the two most common. Semax is used for focus, memory, and mental energy, and can feel stimulating. Selank is used to take the edge off anxiety and lift mood, with a calmer profile, and the two are often paired. Both are approved in Russia and sit at a moderate evidence grade there, but Western replication is limited. Treat "approved in Russia" as a real signal, not a substitute for the trials you would want before betting your mental health on a compound.

DSIP and Pinealon

DSIP (delta sleep-inducing peptide) is used for sleep quality and calming the nervous system. Pinealon (a Khavinson bioregulator) is used for alertness and anti-stress, with an anecdotal shift toward REM sleep. Both sit at a weak evidence grade: old or inconsistent literature, small or animal data. If your low mood is downstream of wrecked sleep, the sleep angle may matter more than any mood-specific claim, but the data here is not strong.

Kisspeptin-10 and oxytocin

Both get cited for mood. Kisspeptin-10 has human neuroendocrine data at a moderate grade. Oxytocin is well studied as a hormone, but its mood and bonding effects are inconsistent between people. "Inconsistent" is the operative word: what one person reports, the next does not.

A note on grading: these tiers (strong, moderate, weak, anecdotal) are the same convention we use across every compound. Moderate is not strong. Weak means proceed as an experiment, not a treatment. None of this is medical advice.

The bigger trap: mood effects that are side effects

Most of the mood changes people attribute to a "mood peptide" are actually second-order effects of a compound they took for something else.

The clearest example is GLP-1s. The "GLP-1 killed my motivation, made me depressed" complaint is real but largely a downstream confounder: low blood pressure, chronic under-eating, depleted electrolytes and micronutrients, and the loss of social eating all drag mood down. Run at the lowest effective dose with nutrition and lifestyle handled, the complaint largely disappears. (There is also evidence GLP-1s reduce alcohol cravings through dopaminergic pathways, which cuts the other way.) We covered this in detail in the GLP-1 motivation dip.

Same story with GHK-Cu, sold for skin, where users report mood and energy shifts with no guide for it: see GHK-Cu's mood and energy reports.

The lesson: before you chase a dedicated mood peptide, rule out whether something already in your stack is moving your mood, in either direction. "It's a peptide" tells you nothing. What matters is which receptor a compound touches and what else it is doing to your body.

Why this is the wrong place to self-experiment

Mood is the one modality where the usual peptide playbook (read a thread, source a vial, titrate, self-report) is most dangerous.

• Anxiety, exhaustion, and depression have medical causes that a compound will mask, not fix. Thyroid problems, anemia, sleep apnea, and clinical depression need a diagnosis, not a peptide.
• The compounds with the best mood evidence are not the ones being sold hardest, and the ones being sold hardest have the least data.
• Self-report on mood is the least reliable signal there is. Without a baseline, you cannot separate a real effect from placebo, regression to the mean, or the sleep you happened to catch up on that week. (More on why in you are running an experiment with no controls.)

This is where the honest answer is to present the options and keep the decision with you and a clinician. A peptide is not a psychiatric treatment, and anyone selling it as one is ahead of the evidence.

One more reason not to build your plan on these

Two of the mood-adjacent compounds here, Semax and DSIP, are on the FDA Pharmacy Compounding Advisory Committee agenda for July 23 to 24, 2026. A yes vote moves them to Category 2 and ends legal compounding access. Building a mental-health routine on a compound whose supply may be cut in weeks is a fragile plan on top of a thin evidence base.

Where this leaves you

If you came to peptides because you feel anxious, exhausted, or low, that is a real problem worth solving. Peptides are not the first tool for it, and the mood-specific ones sit on weaker evidence than the marketing implies. The useful move is to separate what is actually driving your mood (sleep, nutrition, an untreated medical cause, or another compound already in your stack) from the hope that one injection solves it.

If you do go further, vet the source the same way you would for any peptide, and bring the plan to a clinician rather than a forum. The feed tracks the rest of this space as it moves.